Pacer Advisors Inc. Buys 30,931 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Pacer Advisors Inc. lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 597,634 shares of the biotechnology company’s stock after acquiring an additional 30,931 shares during the quarter. Pacer Advisors Inc. owned about 1.34% of United Therapeutics worth $210,869,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in UTHR. JPMorgan Chase & Co. lifted its holdings in United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after purchasing an additional 50,291 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares during the last quarter. Burney Co. boosted its holdings in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after buying an additional 12,705 shares during the period. Bridgewater Associates LP grew its stake in United Therapeutics by 384.3% in the 3rd quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock valued at $22,130,000 after buying an additional 49,003 shares during the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in United Therapeutics by 6.4% in the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after acquiring an additional 4,145 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $370.83 on Monday. The stock has a market capitalization of $16.56 billion, a price-to-earnings ratio of 16.29, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The business’s fifty day moving average price is $365.19 and its two-hundred day moving average price is $356.03. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the company posted $5.38 EPS. Research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Judy D. Olian sold 1,750 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the sale, the director now directly owns 5,655 shares of the company’s stock, valued at $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 139,048 shares of company stock worth $52,435,099 in the last three months. Insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.